老年性黃斑部病變(AMD)及糖尿病視網膜病變(DR):全球醫藥品市場(2011∼2021年)

老年性黃斑部病變(AMD)及糖尿病視網膜病變(DR):全球醫藥品市場(2011∼2021年) 是由出版商Visiongain在2011年07月所出版的。 這份英文市場調查報告書包含204 Pages 價格從美金2331起跳。

簡介

本報告提供全球老年性黃斑部病變(AMD)及糖尿病視網膜病變(DR)市場到2021年為止的收益預測，主要產品，歐美，中國，印度，日本等各不同地區趨勢，再加上主要企業概要等資料彙整，為您概述為以下內容。

第1章 摘要整理

第2章 老年性黃斑部病變(AMD)及糖尿病視網膜病變(DR):簡介

• 視覺原理
  • 人的眼睛
  • 視網膜和視覺過程
• 老年性黃斑部病變(AMD)
  • AMD的早期階段
  • AMD的乾燥症狀
  • 濕性AMD
  • AMD的原因和危險因素
• 糖尿病視網膜病變(DR)
  • 原因和種類
  • 非增殖性視網膜病變
  • 糖尿病黃斑部水腫
  • 增殖性視網膜病變
  • 糖尿病視網膜病變的危險因素
• 診斷
• 免疫學

第3章 全球AMD及DR市場:2011∼2021年

• 全球AMD及DR市場:2011∼2021年
• 市場分類:2011∼2021年
• 眼科市場:2011∼2021年
  • 其他的視網膜疾病

第4章 各地區市場:2011∼2021年

• 美國2010年的AMD，DR市場獨佔
• 美國:2011∼2021年領導市場
  • 美國市場預測
• 日本:第二大市場
  • 日本市場預測
• 歐洲主要5個國家:醫療費急劇上升:2011∼2021年
  • 法國市場
  • 德國市場
  • 英國市場
  • 西班牙市場
  • 義大利市場
• 印度:糖尿病盛行促進市場:2011∼2021年
  • 印度市場預測:2011∼2021年
• 中國:急速擴大的市場:2011∼2021年
  • 中國市場預測

第5章 主要產品

• Lucentis壟斷市場:2011年
• Lucentis (Roche/Novartis):最成功的眼科藥物
  • Lucentis預測:2011∼2021年
• Visudyne (QLT / Novartis):傳統的AMD治療
  • Visudyne預測:2011∼2021年
• Avastin(Roche):Lucentis未經授權的競爭產品
  • CATT研究
  • Avastin預測:2011∼2021年
• Macugen(Pfizer):替代的VEGF拮抗劑
  • Macugen預測:2011∼2021年
• Eylea(Regeneron/Bayer):成為下一波重量級產品
  • Eylea預測:2011∼2021年
• 其他的產品
• 其他的產品預測:2011∼2021年

第6章 AMD及DR的產品開發平台:2011年

• AMD產品
• DR產品

第7章 主要企業

• 醫藥品產業領導者
  • Novartis
  • Roche
  • Pfizer
  • Sanofi
  • 其他的大企業
• 小規模企業

第8章 定性分析

• 建立日益成長的市場
• 一些人認為產品少，不方便，價格昂貴
• 全球人口統計和糖尿病的流行將讓政府的負擔持續增加
• 藥物治療是否是眼科疾病的未來

第9章 調查採訪

第10章 結論

圖表

目錄

Abstract

What are the commercial prospects for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)?

Our new report shows you potential revenues to 2021, discussing commercial opportunities and prospects.

Our report gives you market forecasts to 2021 for those retinal drugs. Discover potential revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions. Find data you need.

See how the drugs Lucentis, Visudyne, Avastin and Macugen can perform to 2021, finding potential revenues. For your needs, we discuss competition in this expanding market.

Our study discusses Roche, Novartis, Pfizer, Sanofi and other companies. There are many opportunities in AMD and DR for large and niche players. Discover prospects for existing competitors and potential market entrants from 2011 to 2021.

There is a strong R&D pipeline for treating retinal disorders. We cover products in development by Regeneron, Bayer, Allergan, OPKO, GSK, Merck, Eli Lilly, Takeda and others. Find R&D trends there.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions

In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. We provide 153 tables and charts and three research interviews (shown in the accompanying lists).

Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• Find revenue predictions to 2021 for the world AMD and DR market and its components, seeing revenue growth
• See revenue forecasts to 2021 for leading products, assessing market potentials and competition
• Discover revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India
• Receive supporting data, including epidemiological trends and projections
• Assess leading companies providing retinal treatments, discovering their activities and outlooks
• Find out how the retinal drug industry can change and adapt from 2011 to 2021
• Investigate competition and opportunities influencing the industry and market
• See what will stimulate and restrain the industry and market from 2011
• Review R&D for AMD and DR, seeing potential for new products and drug types
• Investigate commercial requirements, identifying therapeutic needs and opportunities
• Analyse opportunities and challenges for established and emerging companies
• View opinions from three interviews with authorities on retinal treatments.

There, you find a distinctive mix of quantitative and qualitative analysis with original predictions. We tackle crucial questions for AMD and DR, helping you to stay ahead.

Order our report now to gain industry and market analysis for AMD and DR

Our report is for everybody interested in industry and market analysis for the treatment of retinal disorders. Find trends and answers. Don' t miss out - please order our report now.

Table of Contents

1. Executive Summary

• 1.1. Macular Degeneration (AMD) and Diabetic Retinopathy (DR): Market Overview
• 1.2. Contents of this Report
• 1.3. Research and Analysis Methods

2. AMD and DR: An Introduction

• 2.1. The Biology of Vision
  • 2.1.1. The Human Eye
  • 2.1.2. The Retina and the Vision Process
• 2.2. Age-Related Macular Degeneration (AMD)
  • 2.2.1. Early Stages of AMD
  • 2.2.2. Advanced Dry AMD (Geographic Atrophy)
  • 2.2.3. Wet AMD
  • 2.2.4. Causes and Risk Factors for AMD
• 2.3. Diabetic Retinopathy (DR)
  • 2.3.1. Causes and Types of Diabetic Retinopathy
  • 2.3.2. Non-Proliferative Diabetic Retinopathy
  • 2.3.3. Diabetic Macular Oedema
  • 2.3.4. Proliferative Diabetic Retinopathy
  • 2.3.5. Risk Factors for Diabetic Retinopathy
• 2.4. Diagnosis
• 2.5. Epidemiology

3. The Global AMD and DR Market 2011-2021

• 3.1. Global AMD and DR Market, 2011-2021
• 3.2. Market Breakdown, 2011-2021
• 3.3. The Ophthalmic Market, 2011-2021
  • 3.3.1. Other Retinal Disorders

4. Regional AMD and DR Markets 2011-2021

• 4.1. The US Dominated the AMD and DR Drug Market in 2010
• 4.2. The US: Leading the AMD and DR Market, 2011-2021
  • 4.2.1. Forecast for the US Market, 2011-2021
• 4.3. Japan: Second-Largest Market, 2011-2021
  • 4.3.1. Forecast for the Japanese Market, 2011-2021
• 4.4. The EU Top Five: Rising Healthcare Costs, 2011-2021
  • 4.4.1. Forecast for the French Market, 2011-2021
  • 4.4.2. Forecast for the German Market, 2011-2021
  • 4.4.3. Forecast for the UK Market, 2011-2021
  • 4.4.4. Forecast for the Spanish Market, 2011-2021
  • 4.4.5. Forecast for the Italian Market, 2011-2021
• 4.5. India: Diabetes Epidemic Drives the Market, 2011-2021
  • 4.5.1. Forecast for the Indian Market, 2011-2021
• 4.6. China: The Fastest-Growing Market, 2011-2021
  • 4.6.1. Forecast for the Chinese Market, 2011-2021

5. Leading Products in the AMD and DR Market 2011-2021

• 5.1. Lucentis Dominates the Market in 2011
• 5.2. Lucentis (Roche/Novartis): Most Successful Ophthalmic Drug
  • 5.2.1. Forecast for Lucentis, 2011-2021
• 5.3. Visudyne (QLT / Novartis): Treatment for Classic AMD
  • 5.3.1. Forecast for Visudyne, 2011-2021
• 5.4. Avastin (Roche): Off-Label Competitor to Lucentis
  • 5.4.1. The CATT Study: The Verdict on Avastin versus Lucentis
  • 5.4.2. Forecast for Avastin, 2011-2021
• 5.5. Macugen (Pfizer): Alternative VEGF Antagonist
  • 5.5.1. Forecast for Macugen, 2011-2021
• 5.6. Eylea (Regeneron/Bayer): The Next Blockbuster
  • 5.6.1. Forecast for Eylea, 2011-2021
• 5.7. Other Products in the Market
  • 5.7.1. Treatments for Dry AMD
  • 5.7.2. Treatments for DR
    • 5.7.2.1. Triamcinolone Acetonide (Various Companies)
    • 5.7.2.2. Lisinopril (Various Companies)
    • 5.7.2.3. Avastin (Roche)
    • 5.7.2.4. Dobesilate (Various Companies)
  • 5.7.3. Forecast for Other Products in the Market, 2011-2021

6. The AMD and DR Product Pipeline, 2011

• 6.1. AMD Products
  • 6.1.1. Eylea (Regeneron/Bayer)
  • 6.1.2. Posurdex/SK-503 (Allergan)
  • 6.1.3. Bevasiranib/Cand5 (OPKO)
  • 6.1.4. Pazopanib (GlaxoSmithKline)
  • 6.1.5. NT501 (Neurotech)
  • 6.1.6. Zybrestat (Oxigene/Symphony ViDA)
  • 6.1.7. Brimonidine (Allergan)
  • 6.1.8. Sirolimus (MacuSight/Santen)
  • 6.1.9. Iluvien (Alimera/pSivida)
  • 6.1.10. RTP801i-14/PF-4523655/PF-655 (Quark/Silence/Pfizer)
  • 6.1.11. AGN-745/SIRNA-027 (Merck & Co./Allergan)
  • 6.1.12. ATG-3 (CoMentis)
  • 6.1.13. OT-551 (Othera)
  • 6.1.14. Fenretinide (Sirion Therapeutics)
  • 6.1.15. Early-Stage Products
• 6.2. DR Products
  • 6.2.1. Arxxant (Eli Lilly/Alcon/Takeda)
  • 6.2.2. Vitreosolve (Vitreoretinal Technologies)
  • 6.2.3. Atacand/TCV-116 (AstraZeneca/Takeda)
  • 6.2.4. Microplasmin (Thrombogenics)
  • 6.2.5. Products Also Indicated for AMD
  • 6.2.6. Early-Stage DR Products

7. Leading Companies in the AMD and DR Market, 2011

• 7.1. Pharmaceutical Industry Leaders
  • 7.1.1. Novartis
  • 7.1.2. Roche
  • 7.1.3. Pfizer
  • 7.1.4. Sanofi
  • 7.1.5. Other Big Pharma Players
• 7.2. Smaller Companies
  • 7.2.1. Allergan
  • 7.2.2. BioDiem
  • 7.2.3. CoMentis
  • 7.2.4. Alimera Sciences
  • 7.2.5. Gene Signal
  • 7.2.6. GenVec
  • 7.2.7. ISTA Pharmaceuticals
  • 7.2.8. Shire
  • 7.2.9. KAI Pharmaceuticals
  • 7.2.10. Lpath
  • 7.2.11. Santen
  • 7.2.12. Neurotech
  • 7.2.13. Ophthotech Corporation
  • 7.2.14. OPKO Health
  • 7.2.15. Othera Pharmaceuticals
  • 7.2.16. Oxford BioMedica
  • 7.2.17. Oxigene
  • 7.2.18. Potentia
  • 7.2.19. Regeneron
  • 7.2.20. Sirion Therapeutics
  • 7.2.21. Sirnaomics
  • 7.2.22. AmpliPhi Biosciences Corporation
  • 7.2.23. ThromboGenics

8. The AMD and DR Market: Qualitative Analysis

• 8.1. The AMD and DR Market is Well Established and Growing
• 8.2. Products are Few, Inconvenient and Expensive, Some People Believe
• 8.3. Global Demography and the Diabetes Epidemic Mean Governments Will Keep Paying
• 8.4. Is Pharmaceutical Treatment the Future for Ophthalmics Disorders?

9. Research Interviews

• 9.1. Interview with Professor David T. Shima, University College London
  • 9.1.1. On the Role of VEGF in Retinal Disorders
  • 9.1.2. On Candidate Molecule E10030
  • 9.1.3. On Candidate Molecule JSM 6427
  • 9.1.4. On New Sustained Release Formulations
  • 9.1.5. On Delta-Notch Signalling
  • 9.1.6. On Potential Clinical Crossovers Between Ophthalmology and Oncology
  • 9.1.7. On the Commercial and Clinical Possibilities in the Ophthalmology Market
  • 9.1.8. On the Possibilities of Research into the Endothelial Fenestra
• 9.2. Interview with Dr Edward Feener, Joslin Diabetes Center
  • 9.2.1. On the Kallikrein Pathway in Disease Etiology
  • 9.2.2. On the Use of Proteomics in Research
  • 9.2.3. On Challenges in Diabetic Retinopathy
  • 9.2.4. On Plasma Kallikrein Inhibitors, Prevention, and Other Future Prospects in the Sector
• 9.3. Interview with Dr Paul Ashton, pSivida
  • 9.3.1. On the Challenge of Getting Drugs to the Retina
  • 9.3.2. On pSivida' s Drug Delivery Platforms
  • 9.3.3. On Lucentis, Avastin and VEGF-Trap

10. Conclusions

• 10.1. The AMD and DR Market is Likely to Expand
• 10.2. The Issue of Avastin versus Lucentis Has Dominated the Sector
• 10.3. Regeneron' s Eylea as the Next New Product on the Market
• 10.4. The Pipeline for AMD and DR is Rich and Diverse
• 10.5. Concluding Remarks

List of Tables

• Table 2.1: Leading Causes of Blindness, Number of Cases (m), Proportion of Total (%), 2007
• Table 2.2: Types of CNV in Wet AMD
• Table 2.3: AMD and DR Diagnosis Methods, 2011
• Table 2.4: Incidence (m) and Prevalence (m) of Advanced AMD and DR, 2010
• Table 3.1: Global AMD/DR Market Forecast: Sales ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.2: Global AMD/DR Market Forecast: Sales ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.3: AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2010, 2015, 2021
• Table 3.4: Global AMD and DR Markets Forecast: Sales ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.5: Global AMD and DR Markets Forecast: Sales ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.6: The Ophthalmic Pharmaceuticals Market: Submarkets, Sales ($m), Market Shares (%), 2010
• Table 3.7: Other Retinal Disorders Market Forecast: Sales ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.8: Other Retinal Disorders Market Forecast: Sales ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.9: Some Other Retinal Disorders
• Table 4.1: Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2010
• Table 4.2: Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.3: Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2015
• Table 4.4: Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.5: Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2021
• Table 4.6: US and Leading Five EU National Markets: Drug Prices Relative to the UK, 2008
• Table 4.7: Healthcare Expenditure as Percentage of GDP in Leading Countries, 2010
• Table 4.8: Population (m) Over 65 Years of Age in Leading Countries, at Five-Yearly Intervals, 2000-2030
• Table 4.9: Population (%) Over 65 Years of Age in Leading Countries, at Five-Yearly Intervals, 2000-2030
• Table 4.10: Prevalence of Diabetes in Leading Markets (m and % of Population), 2000 and 2030
• Table 4.11: US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.12: US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.13: Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.14: Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.15: EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2010, 2015, 2021
• Table 4.16: Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.17: Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.18: France: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.19: France: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.20: Germany: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.21: Germany: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.22: UK: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.23: UK: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.24: Spain: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.25: Spain: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.26: Italy: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.27: Italy: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.28: India: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.29: India: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.30: China: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.31: China: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.1: Leading Products in the AMD and DR Drugs Market: Sales ($m), Market Shares (%), 2010
• Table 5.2: Leading Products in the AMD and DR Drugs Market: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.3: Leading Products in the AMD and DR Drugs Market: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.4: Lucentis Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.5: Lucentis Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.6: Visudyne Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.7: Visudyne Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.8: Avastin Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.9: Avastin Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.10: Macugen Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.11: Macugen Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.12: Eylea Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.13: Eylea Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.14: Other Products Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.15: Other Products Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 6.1: AMD Pipeline, Phase II and Later, 2011
• Table 6.2: AMD Pipeline, Phase I and Preclinical, 2011
• Table 6.3: DR Pipeline, Phase II and Later, 2011
• Table 6.4: DR Pipeline, Phase I and Preclinical, 2011
• Table 8.1: SWOT Analysis of AMD and DR Market, 2011

List of Figures

• Figure 2.1: Leading Causes of Blindness, Number of Cases (m), Proportion of Total (%), 2007
• Figure 2.2: Stages and Progression of AMD
• Figure 2.3: Types of CNV in Wet AMD, Approximate Proportion of Cases (%), 2010
• Figure 2.4: Incidence (m) and Prevalence (m) of Advanced AMD and DR, 2010
• Figure 3.1: Global AMD/DR Market Forecast: Sales ($m), 2010-2015
• Figure 3.2: Global AMD/DR Market Forecast: Sales ($m), 2016-2021
• Figure 3.3: AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2010
• Figure 3.4: AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2015
• Figure 3.5: AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2021
• Figure 3.6: Global AMD and DR Markets Forecast: Sales, 2010-2015
• Figure 3.7: Global AMD and DR Markets Forecast: Sales, 2016-2021
• Figure 3.8: Global AMD and DR Markets Forecast: Market Shares (%), 2010-2015
• Figure 3.9: Global AMD and DR Markets Forecast: Market Shares (%), 2016-2021
• Figure 3.10: The Ophthalmic Pharmaceuticals Market: Sales ($m), 2010
• Figure 3.11: The AMD and DR Market as a Proportion of the Ophthalmic Pharmaceuticals Market: (%), 2010-2021
• Figure 3.12: Other Retinal Disorders Market Forecast: Sales ($m), 2010-2015
• Figure 3.13: Other Retinal Disorders Market Forecast: Sales ($m), 2016-2021
• Figure 4.1: Leading National Markets, AMD and DR drugs: Sales ($m), Market Shares (%), 2010
• Figure 4.2: Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Figure 4.3: Leading Five EU National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Figure 4.4: Leading National Markets, AMD and DR drugs: Sales ($m), Market Shares (%), 2015
• Figure 4.5: Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Figure 4.6: Leading Five EU National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Figure 4.7: Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2021
• Figure 4.8: US and Leading Five EU National Markets: Drug Prices Relative to UK, 2008
• Figure 4.9: Healthcare Expenditure as Percentage of GDP, Leading Countries, 2010
• Figure 4.10: Population (m) Over 65 Years of Age in Leading Countries, 2000-2030
• Figure 4.11: Population (m) Over 65 Years of Age in Leading Five EU Countries, 2000-2030
• Figure 4.12: Population (%) Over 65 Years of Age in Leading Countries, 2000-2030
• Figure 4.13: Population (%) Over 65 Years of Age in Leading Five EU Countries, 2000-2030
• Figure 4.14: Prevalence of Diabetes in Leading Markets (m), 2000 and 2030
• Figure 4.15: Prevalence of Diabetes in Leading Markets (%), 2000 and 2030
• Figure 4.16: US: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.17: US: Population Over 65 (%), Population with Diabetes (m), 2000 and 2030
• Figure 4.18: US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Figure 4.19: US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Figure 4.20: Japan: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.21: Japan: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.22: Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Figure 4.23: Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Figure 4.24: EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2010
• Figure 4.25: EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2015
• Figure 4.26: EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2021
• Figure 4.27: EU Leading Five Markets: Healthcare Expenditure as Fraction of GDP (%), Population Over 65 (%), 2010
• Figure 4.28: Leading Five EU Markets: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.29: Leading Five EU Markets: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.30: Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.31: Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 4.32: France: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.33: France: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.34: France: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.35: France: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 4.36: Germany: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.37: Germany: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.38: Germany: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.39: Germany: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 4.40: UK: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.41: UK: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.42: UK: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.43: UK: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 4.44: Spain: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.45: Spain: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.46: Spain: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.47: Spain: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 4.48: Italy: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.49: Italy: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.50: Italy: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.51: Italy: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 4.52: India: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.53: India: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.54: India: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.55: India: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 4.56: China: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
• Figure 4.57: China: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
• Figure 4.58: China: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
• Figure 4.59: China: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
• Figure 5.1: Leading Products in the AMD and DR Drugs Market: Sales ($m), Market Shares (%), 2010
• Figure 5.2: Lucentis Market Forecast: Sales ($m), 2010-2015
• Figure 5.3: Lucentis Market Forecast: Sales ($m), 2016-2021
• Figure 5.4: Visudyne Market Forecast: Sales ($m), 2010-2015
• Figure 5.5: Visudyne Market Forecast: Sales ($m), 2016-2021
• Figure 5.6: Avastin Market Forecast: Sales ($m), 2010-2015
• Figure 5.7: Avastin Market Forecast: Sales ($m), 2016-2021
• Figure 5.8: Macugen Market Forecast: Sales ($m), 2010-2015
• Figure 5.9: Macugen Market Forecast: Sales ($m), 2016-2021
• Figure 5.10: Eylea Market Forecast: Sales ($m), 2010-2015
• Figure 5.11: Eylea Market Forecast: Sales ($m), 2016-2021
• Figure 5.12: Other Products Market Forecast: Sales ($m), 2010-2015
• Figure 5.13: Other Products Market Forecast: Sales ($m), 2016-2021

Companies Listed

• Abbott Laboratories
• Advanced Vision Science
• Agency for Nutrition and Food Safety (Spain)
• Alcon Laboratories
• Alimera Sciences
• Allergan
• American Academy of Ophthalmology (AAO)
• American Society of Retina Specialists (ASRS)
• AmpliPhi Biosciences Corporation
• Assogenerici (Italian Association of Generic Medicines Industry)
• Astellas Pharma
• AstraZeneca
• Aurobindo Pharma
• Bausch & Lomb
• Bayer Healthcare
• Biocon
• BioDiem
• BioInvent International
• Bristol-Myers Squibb
• Cambridge University
• Centre for Molecular and Vascular Biology, KU Leuven
• CIBA Vision
• Cipla
• Claris Lifesciences
• CoMentis
• Control Delivery Systems
• Daiichi Sankyo
• Delenex Therapeutics
• Diabetic Retinopathy Clinical Research Network (DRCR)
• Dr. Reddy' s Laboratories
• Eli Lilly
• Emory University
• ESBATech
• Esteve
• European Medicines Agency (EMA)
• Eyetech Pharmaceuticals
• Food and Drug Administration (US FDA)
• Fovea Pharmaceuticals
• Gene Signal
• Genentech
• GenVec
• GlaxoSmithKline
• Harvard Medical School
• iCo Therapeutics
• Institute of Experimental Medicine (St. Petersburg, Russia)
• Intas Biopharmaceuticals
• International Diabetes Foundation
• Isis Pharmaceuticals
• ISTA Pharmaceuticals
• Jerini
• Joslin Diabetes Center
• KAI Pharmaceuticals
• Lpath
• Ludwig-Maximilians-Universitat
• Lupin Pharma
• MacuSight
• MedImmune
• Merck & Co.
• Merial
• National Eye Institute (NEI)
• National Health Service (NHS)
• National Institute for Clinical Excellence (NICE)
• Neurotech
• New England Journal of Medicine (NEJM)
• Nobilon International
• Novartis
• Novo Nordisk
• Oklahoma Medical Research Foundation
• OM Pharmaceuticals
• Onco Therapies
• Ophthotech
• Opko Health
• Othera Pharmaceuticals
• Oxford BioMedica
• Oxigene
• Pfizer
• Piramal Healthcare
• PlaNrt Finance
• Potentia Pharmaceuticals
• Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
• pSivida
• Purdue University
• QLT
• Quark Pharmaceuticals
• Ranbaxy Laboratories
• Regeneron
• Reliance Life Sciences
• ReVision Therapeutics
• Roche
• Sanofi
• Santen Pharmaceutical
• Sanwa Kagaku Kenkyusho (a subsidiary of Suzuken)
• Shandong University
• Shanghai Institute for Biological Sciences
• Shire
• Silence Therapeutics
• Sirion Therapeutics
• Sirna Therapeutics
• Sirnaomics
• State Food and Drug Administration (China)
• Strides Arcolab
• SurModics
• Symphony ViDA
• Takeda Pharmaceutical Company
• TargeGen
• ThromboGenics
• University College London
• University of Florida
• University of Kentucky College of Medicine
• Vitreoretinal Technologies
• Wockhardt
• World Health Organization (WHO)

相關商品

藥物開發相關市場調查報告書

分析工具：癌症治療的蛋白激脢抗化劑
Analytical Tool - Protein Kinase Inhibitors in Oncology
價格 : US $ 6674
出版日期 : 2012年05月

乳癌，肺癌，Protein Kinase抗化劑:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

白血病，肺癌，Protein Kinase抗化劑:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Protein Kinase Inhibitors
價格 : US $ 5175
出版日期 : 2012年05月

Visiongain發行的製藥相關市場調查報告書

醫藥品主要企業系列:前50大學名藥廠商企業 2012-2022年

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

眼科用醫藥品的全球市場預測

Ophthalmic Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

主要抗癌藥及相關市場:2012-2022年

Leading Anti-Cancer Drugs and Associated Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!